### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPE	ROVAL
OMB Number:	3235-0287
Estimated average I	burden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner		
OF TEMPER O	` '								<i>i</i> )
4	te Original F	iled(N	Month/Day/Y	ear)		Individual or Joint/Group Filing(Check Applicable Line)     X_Form filed by One Reporting Person     Form filed by More than One Reporting Person			
(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
2. Transaction Date (Month/Day/Year)	Execution Date, if any	execution Date, if Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Owned Following Reported Transaction(s)	Ownership Form:	Beneficial
	(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	,	or Indirect (I)	Ownership (Instr. 4)
12/10/2019		M		8,000	A	\$ 8.03	10,273	D	
12/10/2019		S		8,000	D	\$ 26.37	2,273	D	
ss of securities ben	eficially owned direc		•	ons who	respon	d to the	collection of information contained	lin SEC	1474 (9-02)
	(Middle) SUITE 9  (Zip)  2. Transaction Date (Month/Day/Year)  12/10/2019  12/10/2019	NEOGENOMICS  (Middle) SUITE 9  3. Date of Earliest Tra 12/10/2019  4. If Amendment, Da  (Zip)  2. Transaction Date (Month/Day/Year)  2A. Deemed Execution Date, if any (Month/Day/Year)  12/10/2019  12/10/2019	NEOGENOMICS INC [NEOGENOMICS INC [NEOGEN	NEOGENOMICS INC [NEO]  (Middle) SUITE 9  3. Date of Earliest Transaction (Month/12/10/2019)  4. If Amendment, Date Original Filed(N  2. Transaction Date (Month/Day/Year)  2. Deemed Execution Date, if any (Month/Day/Year)  Code (Instr. 8)  Code V  12/10/2019  M  12/10/2019  S  ss of securities beneficially owned directly or indirectly.	(Middle) SUITE 9  3. Date of Earliest Transaction (Month/Day/Year 12/10/2019  4. If Amendment, Date Original Filed(Month/Day/Y 22)  2. Transaction Date (Month/Day/Year)  2. Transaction Execution Date, if (Month/Day/Year)  (Month/Day/Year)  2. Code (Instr. 3)  Code V Amount 2/10/2019  M 8,000  12/10/2019  S 8,000  ss of securities beneficially owned directly or indirectly.	NEOGENOMICS INC [NEO]  (Middle) SUITE 9  3. Date of Earliest Transaction (Month/Day/Year) 12/10/2019  4. If Amendment, Date Original Filed(Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  3. Transaction Code (Instr. 8)  4. Securities Acq (A) or Disposed of (Instr. 8)  (Month/Day/Year)  12/10/2019  M 8,000 A  12/10/2019  S 8,000 D	NEOGENOMICS INC [NEO]	NEOGENOMICS INC [NEO]  (Middle) SUITE 9  3. Date of Earliest Transaction (Month/Day/Year)  12/10/2019  4. If Amendment, Date Original Filed(Month/Day/Year)  (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Execution Date, (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  2. Toda (A) or Disposed of (D) (Instr. 3, 4 and 5)  (Month/Day/Year)  (A) or Disposed of (D) (Instr. 3 and 4)  (A) or Disposed of (D) (Instr. 3 and 4)  (A) or Disposed of (D) (Instr. 3 and 4)  (A) or Disposed of (D) (Instr. 3 and 4)  (A) or Disposed of (D) (Instr. 3 and 4)  (A) or Disposed of (D) (Instr. 3 and 4)  (A) or Disposed of (D) (Instr. 3 and 4)  (A) or Disposed of (D) (Instr. 3 and 4)  (A) or Disposed of (D) (Instr. 3 and 4)  (B) Owned Following Reported (Instr. 3 and 4)  (B) Owned Following Reported (Instr. 3 and 4)  (Code V Amount (D) Price (D) (Instr. 3 and 4)  (Code V Amount (D) Price (D) (Instr. 3 and 4)	NEOGENOMICS INC [NEO]   Director   10% Owner   10% Owner   2/10/2019   Line   10% Owner   10% Owner   10% Owner   2/10/2019   Line   2

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

this form are not required to respond unless the form displays a

currently valid OMB control number.

(cigi, putis, turismos, options, convertible securities)															
1. Title of		3. Transaction		4.				6. Date Exercisable and					9. Number of		11. Nature
Security	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Code		Der Sec Acc (A) Disj of (			(Instr. 3 and 4)		(Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Derivative Security: Direct (D) or Indirect	of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$ 8.03	12/10/2019		M			8,000	02/26/2019 <sup>(1)</sup>	02/26/2023	Common Stock	8,000.00	\$ 0	40,000	D	
Stock Option (Right to Buy)	\$ 9.07							10/18/2018 <sup>(2)</sup>	10/18/2022	Common Stock	25,000.00		25,000	D	
Stock Option (Right to Buy)	\$ 19.60							03/01/2020(3)	03/01/2024	Common Stock	13,894.00		13,894	D	

### **Reporting Owners**

Reporting Owner Name / Address			Relationships				
	Director	10% Owner	Officer	Other			
McKenzie Kathryn B 12701 COMMONWEALTH DRIVE SUITE 9 FORT MYERS, FL 33913			Chief Accounting Officer				

### **Signatures**

/s/ Kathryn McKenzie	12/12/2019

**Signature of Reporting Person	Date			

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On February 26, 2018, Ms. McKenzie was granted an option to purchase 48,000 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date.
- (2) On October 18, 2017, Ms. McKenzie was granted an option to purchase 25,000 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date.
- (3) On March 1, 2019, Ms. McKenzie was granted an option to purchase 13,894 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first four anniversary dates of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.